Register      Login
Australian Journal of Chemistry Australian Journal of Chemistry Society
An international journal for chemical science

Articles citing this paper

Inhibitors of Galectins and Implications for Structure-Based Design of Galectin-Specific Therapeutics

Helen Blanchard A B , Khuchtumur Bum-Erdene A and Matthew W. Hugo A
+ Author Affiliations
- Author Affiliations

A Institute for Glycomics, Griffith University, Gold Coast Campus, Queensland 4222, Australia.

B Corresponding author. Email: h.blanchard@griffith.edu.au




Associate Professor Helen Blanchard (Ph.D. (1990), Chemistry and small-molecule crystallography, University of London, UK) undertook post-doctoral research in protein X-ray crystallography and drug-design in academia and industry within Canada, USA, Switzerland and Australia. In 2002 Helen established a protein X-ray crystallography structural biology group at the Institute for Glycomics, Griffith University. As recognition of her international contribution to structural biology and chemistry she was admitted as fellow of the Royal Society of Chemistry (FRSC) in 2006. Her research involves determination of atomic protein structure, analysis of protein-ligand interactions and application of this information in understanding protein function and for structure based drug-design. Her research group has a major focus on lectins critical to disease progression including her research program on galectins that have importance in serious conditions including cancer.



Khuchtumur Bum-Erdene completed his Bachelors degree in Chemistry (2010) at Indiana University-Purdue University Indianapolis in USA and is a Ph.D. student at the Institute for Glycomics, Griffith University under the supervision of Associate Professor Helen Blanchard. His research focuses on the structure-function of the galectin family of proteins and structure-based drug design.



Matt Hugo completed his Bachelor of Biomolecular Science (Advanced) with Honours (2013) at Griffith University and is a Ph.D. student under the supervision of Associate Professor Helen Blanchard at the Institute for Glycomics, Griffith University. His research encompasses structure-based drug design and synthesis of inhibitors targeting galectins.

Australian Journal of Chemistry 67(12) 1763-1779 https://doi.org/10.1071/CH14362
Submitted: 6 June 2014  Accepted: 10 July 2014   Published: 29 September 2014



20 articles found in Crossref database.

Sugared biomaterial binding lectins: achievements and perspectives
Bojarová P., Křen V.
Biomaterials Science. 2016 4(8). p.1142
Evaluation of Self-Assembled Glycopeptide Nanofibers Modified with N,N′-Diacetyllactosamine for Selective Galectin-3 Recognition and Inhibition
Restuccia Antonietta, Fettis Margaret M., Farhadi Shaheen A., Molinaro Matthew D., Kane Bryant, Hudalla Gregory A.
ACS Biomaterials Science & Engineering. 2018 4(10). p.3451
Inhibition of galectins in cancer: Biological challenges for their clinical application
Laderach Diego José, Compagno Daniel
Frontiers in Immunology. 2023 13
Synthesis of the Thomsen-Friedenreich-antigen (TF-antigen) and binding of Galectin-3 to TF-antigen presenting neo-glycoproteins
Hoffmann Marius, Hayes Marc R., Pietruszka Jörg, Elling Lothar
Glycoconjugate Journal. 2020 37(4). p.457
International Year of Crystallography
Batten Stuart R., Kobe Bostjan, Guddat Luke
Australian Journal of Chemistry. 2014 67(12). p.1718
High-Affinity N-(2-Hydroxypropyl)methacrylamide Copolymers with Tailored N-Acetyllactosamine Presentation Discriminate between Galectins
Tavares Marina Rodrigues, Bláhová Markéta, Sedláková Lieselotte, Elling Lothar, Pelantová Helena, Konefał Rafał, Etrych Tomáš, Křen Vladimír, Bojarová Pavla, Chytil Petr
Biomacromolecules. 2020 21(2). p.641
Novel Selective Galectin-3 Antagonists Are Cytotoxic to Acute Lymphoblastic Leukemia
Bum-Erdene Khuchtumur, Collins Patrick M., Hugo Matthew W., Tarighat Somayeh S., Fei Fei, Kishor Chandan, Leffler Hakon, Nilsson Ulf. J., Groffen John, Grice I. Darren, Heisterkamp Nora, Blanchard Helen
Journal of Medicinal Chemistry. 2022 65(8). p.5975
Galectin-3 Involvement in Cognitive Processes for New Therapeutic Considerations
Mijailović Nataša R., Vesic Katarina, Arsenijevic Dragana, Milojević-Rakić Maja, Borovcanin Milica M.
Frontiers in Cellular Neuroscience. 2022 16
Galectin-1 inhibitors and their potential therapeutic applications: a patent review
Blanchard Helen, Bum-Erdene Khuchtumur, Bohari Mohammad Hussaini, Yu Xing
Expert Opinion on Therapeutic Patents. 2016 26(5). p.537
Turning-Off Signaling by Siglecs, Selectins, and Galectins: Chemical Inhibition of Glycan-Dependent Interactions in Cancer
Cagnoni Alejandro J., Pérez Sáez Juan M., Rabinovich Gabriel A., Mariño Karina V.
Frontiers in Oncology. 2016 6
Galectin–Carbohydrate Interactions in Biomedicine and Biotechnology
Laaf Dominic, Bojarová Pavla, Elling Lothar, Křen Vladimír
Trends in Biotechnology. 2019 37(4). p.402
An updated patent review of galectin-1 and galectin-3 inhibitors and their potential therapeutic applications (2016–present)
Sethi Aaftaab, Sanam Swetha, Alvala Ravi, Alvala Mallika
Expert Opinion on Therapeutic Patents. 2021 31(8). p.709
Chemo‐Enzymatic Synthesis of Branched N‐Acetyllactosamine Glycan Oligomers for Galectin‐3 Inhibition
Laaf Dominic, Steffens Hanna, Pelantová Helena, Bojarová Pavla, Křen Vladimír, Elling Lothar
Advanced Synthesis & Catalysis. 2017 359(22). p.4015
Selection of galectin‐3 ligands derived from genetically encoded glycopeptide libraries
Vinals Daniel Ferrer, Kitov Pavel I., Tu Zhijay, Zou Chunxia, Cairo Christopher W., Lin Hans Chun‐Hung, Derda Ratmir
Peptide Science. 2019 111(1).
Engineering galectin–glycan interactions for immunotherapy and immunomodulation
Farhadi Shaheen A, Hudalla Gregory A
Experimental Biology and Medicine. 2016 241(10). p.1074
Targeting galectin-driven regulatory circuits in cancer and fibrosis
Mariño Karina V., Cagnoni Alejandro J., Croci Diego O., Rabinovich Gabriel A.
Nature Reviews Drug Discovery. 2023 22(4). p.295
Emerging Role of Galectins as Molecular Targets for Cancer Therapy: A Review
Shaik Mohammad Anjum, Hong- Wai Tham
Malaysian Journal of Medicine and Health Sciences. 2023 19(5). p.378
Thiodigalactoside–Bovine Serum Albumin Conjugates as High-Potency Inhibitors of Galectin-3: An Outstanding Example of Multivalent Presentation of Small Molecule Inhibitors
Zhang Hao, Laaf Dominic, Elling Lothar, Pieters Roland J.
Bioconjugate Chemistry. 2018 29(4). p.1266
Biocompatible glyconanomaterials based on HPMA-copolymer for specific targeting of galectin-3
Bojarová P., Tavares M. R., Laaf D., Bumba L., Petrásková L., Konefał R., Bláhová M., Pelantová H., Elling L., Etrych T., Chytil P., Křen V.
Journal of Nanobiotechnology. 2018 16(1).
Galectins and galectin-mediated autophagy regulation: new insights into targeted cancer therapy
Liu Dan, Zhu Hongtao, Li Chuanzhou
Biomarker Research. 2023 11(1).

Committee on Publication Ethics


Abstract Export Citation Get Permission